Multiple myeloma (MM) is a heterogeneous group of disorders both genotypically and phenotypically. Response to thalidomide-based induction therapy in newly diagnosed patients varies significantly in published clinical trials. Proteomic analysis was performed on 39 newly diagnosed MM patients treated with a thalidomide-based regimen (22 responders; 17 non-responders) using immunodepletion, 2-D DIGE analysis and mass spectrometry. Zinc-a-2-glycoprotein (ZAG), vitamin D-binding protein (VDB), serum amyloid-A protein (SAA) and b-2-microglobulin (B2M) had statistically significant higher concentrations in non-responders compared to responders, while haptoglobin (Hp) had a lower concentration. ELISAs were used to validate the candidate protein biomarkers using unfractionated serum from 51 newly diagnosed MM patients (29 responders; 22 non-responders). Using logistic regression, the best possible area under the curve (AUC) was 0.96 using ZAG, VDB and SAA in combination. Leave-one-out-cross-validation (LOOCV) indicated an overall predictive accuracy of 84% with associated sensitivity and specificity values of 81.8 and 86.2%, respectively. Subsequently, 16 of 22 thalidomide-refractory patients successfully achieved complete response or very good partial response using second-line treatment suggesting that the biomarker profile is specific to thalidomide response rather than identifying patients with MM refractory to all therapies. Using a novel panel of predictive biomarkers, the feasibility of predicting response to thalidomide-based therapy in previously untreated MM has been demonstrated.
Introduction
Multiple myeloma (MM) is characterized by the proliferation of malignant plasma cells within a complex inter-dependent cellular network in the bone marrow (BM). Although MM remains an incurable blood cancer in the majority of patients, the development of novel therapies has dramatically increased response rates and long-term disease control is now attainable in a significant proportion of patients [1, 2] .
A minority of centers has access to gene expression profiling and can stratify patients in terms of high-and lowrisk disease, thus potentially individualizing treatment [3] . Molecular and cytogenetic analysis can identify high-risk groups but these facilities are not available in all centers. The more widely available International Staging System (ISS) allows clinicians to identify prognostic groups based on b-2-microglobulin (B2M) and serum albumin levels [4, 5] . However, despite major advances in our understanding of this complex disease, a relatively standard remission-induction therapeutic approach is typically used in patients in similar categories of age and performance status by the majority of groups [6, 7] .
Thalidomide is an oral immunomodulatory [8] drug that has been shown to be highly active against MM, with response rates of 30-70% [9] . Recent long-term follow-up data indicate that patients exposed to thalidomide early in their treatment history obtain durable benefit [10] . Therefore, it is likely that thalidomide and its emerging analogues such as lenalidomide will remain a central component of anti-MM therapy in the future. Serious side effects observed with use of thalidomide in MM include thrombo-embolic disease and peripheral neuropathy. Neuropathy can be irreversible and may preclude the use of other potentially neuropathic therapies including bortezomib, thereby compromising survival.
In this study, we have focused specifically on identifying a biomarker profile that correlates with response rate to thalidomide-based regimens in newly diagnosed patients with MM. We have attempted to devise a proteomic profile using an accessible platform that will assist clinicians in individualizing treatment by identifying patients that will have a high likelihood of response to thalidomide-based therapy. If validated in prospective studies, this profile could allow the physician to choose an alternative therapy in patients predicted to be resistant to thalidomide-based treatment thereby avoiding ineffective, potentially costly treatment and exposure of the patient to unnecessary side effects.
Materials and methods

Patients and sample collection
Serum samples from 51 consecutive newly diagnosed MM patients who were having initial treatment with thalidomidebased regimens were analyzed. Samples were obtained at diagnosis and prior to commencement of therapy. The samples were collected according to standard phlebotomy procedures from consented patients. Ethical consent was granted from the Mater Misericordiae University Hospital, Dublin, Ireland, ethics committee. Ten milliliters of blood sample was collected into additive free blood tubes and was allowed to clot for 30 min to 1 h at room temperature. Samples were coded and transported on ice to the laboratory. The serum was denuded by pipette from the clot and place into a clean tube. The tubes were centrifuged at 400 relative centrifugal force (rcf) for 30 min at 41C. Serum was aliquoted in the cryovial tubes, labeled and stored at À801C until time of analysis. The time from sample procurement to storage at À801C was less than 3 h. Each serum sample underwent no more than three freeze/thaw cycles prior to analysis.
Removal of high-abundance proteins from serum samples
Samples were prepared as outlined previously [11] . Briefly, diluted samples (Buffer A) were centrifuged to remove lipids and particulates. The Human Multiple Affinity Removal System (MARS) column was employed to remove 14 of the most abundant proteins (albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin (Hp), fibrinogen, a-2-macroglobulin, a-1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein AII, complement C3 and transthyretin). For each sample, a low-abundance fraction was collected and concentrated using 5-kDa molecular weight cut-off spin concentrators (Agilent Technologies). The concentrated depleted serum samples were collected and immediately transferred and stored at À801C until further analysis. The depletion protocol was found to be reproducible as demonstrated by Western blot analysis using an anti-albumin antibody, which confirmed the absence of albumin from the immunodepleted fraction (results not shown).
Preparation for 2-D electrophoresis
Proteins from the immunodepleted serum samples were precipitated prior to labeling using a 2-D Cleanup Kit (Biorad). The protein pellets were resuspended in icecold DIGE lysis buffer (20 mM Tris, 7 M Urea, 2 M Thiourea, 4% CHAPS, pH 8.5). Protein quantification was performed using the Quick Start Bradford Protein Assay (Biorad) using BSA as a protein standard [11] .
2-D DIGE
Depleted serum samples were labeled with N-hydroxy succinimidyl ester-derivatives of the cyanine dyes Cy2, Cy3 and Cy5 following a standard protocol [11] . Immobilized 24-cm linear pH gradient (IPG) strips, pH 3-11 NL, were rehydrated in rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG Buffer, 50 mM DTT) overnight, according to the standard guidelines [11, 12] . Isoelectric focusing (IEF) was performed using an IPGphor apparatus (GE Healthcare) for a total of 40 kV/h at 201C. Equilibrated IPG strips were placed on top of 12.5% uniform polyacrylamide gels cast between low-fluorescence glass plates. Strips were sealed on the top of the gels using a sealing solution (0.5% w/v low-melting-point agarose in running buffer containing bromphenol blue). Gels were run on the Ettan Dalt 12 apparatus (GE Healthcare) using a two-step protocol, 2.5 W/gel for 30 min and then 100 W in total at 101C until the dye front had run off the bottom of the gels.
DeCyder analysis
Gels were scanned using the Typhoon 9400 Variable Mode Imager (GE Healthcare) to generate images at the appropriate excitation and emission wavelengths from the Cy2-, Cy3-and Cy5-labeled samples. Subsequently, the gel images were cropped using ImageQuant software (GE Healthcare) and imported into Decyder 6.5 software. Decyder 6.5 was used to compare the immunodepleted serum from responders versus non-responders to generate lists of differentially expressed (DE) proteins [11, 13] . The differential in gel analysis (DIA) module was used to assign spot boundaries and to calculate parameters such as normalized spot volume. The BVA mode of DeCyder 6.5 was then used to match all paired image comparisons from difference in-gel analysis for a comparative cross gel statistical analysis. At this stage, operator intervention was required for more accurate matching. If the matching in an area required correction, the current matches were broken and remade with the appropriate spots [11, 12] .
Spot digestion and identification by mass spectrometry
Proteins of interest were picked from preparative gels containing 400 mg of protein stained with Colloidal Coomassie Blue (CBB) stain (Sigma) using the Ettan Spot Picker robot (GE Healthcare). Tryptic digestions were performed on the proteins of interest according to standard protocols [11] . Samples were analyzed using a 1-D LC-MS/MS method run on an Ettan MDLC system (GE Healthcare) in high-throughput configuration directly connected to a Finnegan LTQ (Thermo Electron). Samples were initially concentrated and desalted on RPC trap columns (Zorbax 300SB C18, 0.3 mm Â 5 mm, Agilent Technologies). Subsequently, peptides were separated on a nano-RPC column (Zorbax 300SB C18, 0.075 mm Â 100 mm, Agilent Technologies) using a linear acetonitrile gradient from 0 to 65% ACN (Sigma) over 60 min. All buffers used for nano-LC separation contained 0.1% formic acid (Fluka) as the ion pairing reagent [14] . Identification of proteins was carried out using the Turbo-SEQUEST algorithm in the BioWorks 3.1 software package (Thermo Electron) and the Swiss-Prot human database (Swiss Institute of Bioinformatics, Geneva, Switzerland). Peptides were further evaluated using charge state versus cross-correlation number (XCorr). The following SEQUEST criteria were selected for high-confidence peptide identification: XCorr41.5 for singly charged ions, XCorr42.0 for doubly charged ions, and XCorr42.5 for triply charged ions, together with a minimum of two matched peptides for each protein [14, 15] .
ELISA
ELISAs were used to confirm the differential expression of the five potential biomarkers discovered using 2-D DIGE analysis. ELISA-based validation was carried out using raw unfractionated serum samples from the original cohort of patients. Each sample was analyzed in duplicate using the following commercially available kits: for the measurement of human serum amyloid-A protein (SAA) (Invitrogen), serum Hp (AssayMax), zinc-a-2-glycoprotein (ZAG) (BioVendor), B2M and vitamin D-binding protein (VDB) (Immunodiagnostic) kits were used. The ELISA assays were performed according to each manufacturer's protocol and guidelines. The optical density (OD) was measured using a micro-plate reader (Bio-Tek) and the concentration of each protein in the serum samples was determined by comparing the OD of the samples against the respective standard curve provided by the kit.
Statistical analysis
DIGE gels were exported for image analysis using the BVA module of Decyder 6.5 software (GE Healthcare) for quantitation of protein abundance levels. Following confirmation of appropriate spot detection, matching, normalization and spot statistics were reviewed. The normalized volume of a spot was compared in all the gels between each group. Spots that were found to be statistically significant by univariate analysis (t-testr0.01) were selected for further investigation.
Multivariate logistic regression (LR) and receiver operating characteristic (ROC) curve analysis were carried out in the freely available statistical software R (http://www. r-project.org/). The ROC curves were used to interpret the utility of LR models for various combinations of the DE proteins. The probability of correct prediction for a given model was calculated from the ROC curve by determining the area under curve (AUC). Proteins and combinations of proteins returning the largest AUC values are deemed the most effective for the discrimination of responders from non-responders [16] .
Akaike's Information Criterion (AIC) was also used as an additional factor to select the best combination of biomarkers. AIC is a commonly used measure to select between competing statistical models. The AIC is a trade off between the goodness of fit and model complexity, i.e. the number of parameters required (in this case proteins).
Sensitivity and specificity values were calculated for the best combination of biomarkers. Sensitivity is defined as the percentage of all non-responders who were refractory to a thalidomide-based treatment regime correctly identified as having this phenotype based on the panel of protein biomarkers (the true positive rate). Specificity is defined as the percentage of all responders who were sensitive to a thalidomide-based treatment regime correctly identified as having this phenotype based on the panel of protein biomarkers (the true negative rate).
As an additional measure of the potential of these biomarkers to accurately predict response to thalidomidebased therapy, a commonly used internal validation technique known as leave-one-out-cross-validation (LOOCV) was performed. During the LOOCV procedure, data from a single observation are removed from the data set and the remaining samples are then utilized to construct a LR model. The ''test'' sample is presented to the trained model and the performance assessed; LOOCV continues until each observation is designated as the ''test.'' The average performance over the 51 tests is reported as the LOOCV accuracy.
Results
Sample set
The mean age of the patient group was 68 SD76.95 years (range 52-81 years); 27 were male and 24 female. Based on day-100 re-staging investigations and using the International Myeloma Working Group (IMWG) uniform response criteria for MM [17, 18] , 29 responders and 22 non-responders to thalidomide-based therapy were identified. The mean age was 66 SD76.80 years (range 52-81 years) for responders and 70 SD76.69 years (range 57-79 years) for non-responders. Based on the ISS classification [19] , 6 responding patients had stage I, 15 had stage II and 8 had stage III disease. Two non-responders had stage I, 11 had stage II and 9 had stage III disease. In the responders group, 24 patients were treated with thalidomide and dexamethasone (TD), 3 with thalidomide, cyclophosphamide and dexamethasone (CTD) and 2 with melphalan, prednisone and thalidomide (MPT). In the non-responder group, 17 patients received thalidomide and dexamethasone, 4 received thalidomide, cyclophosphamide and dexamethasone and 1 patient received melphalan, prednisone and thalidomide. Median follow-up was 18 months (range 9-27 months). In the responder group, 9 patients achieved complete response (CR) and 20 achieved very good partial response (VGPR). Five non-responders had Stable disease (SD) and the remaining 17 had Progressive disease (PD) ( Table 1 ). Time to progression (TTP) was defined as the time from the start of thalidomide-based regimen to the date of documented progression. Of the 29 responders, 8 eventually relapsed with median TTP of 15 months (range 11-18 months). However, median TTP has not been calculated for this group as 21 patients remain in CR or VGPR.
Proteomic profiling
Proteins were precipitated from the low-abundance immunodepleted fraction, resuspended in lysis buffer, fluorescently labeled and analyzed by 2-D DIGE using an internal standard design. This analysis was performed on 39 newly diagnosed MM patients (22 responders; 17 non-responders). Spot maps were generated and maps were aligned with a master spot map; relative abundance values were generated for each of 886 protein spots that were common to more than 90% of gels. Based on 2-D DIGE analysis, protein spots with a fold change of Z1.25 in abundance level and a t-test of r0.01 were selected. Using these criteria, five individual DE proteins spots were detected. Four proteins were increased in abundance level, and one was decreased in abundance level in thalidomide non-responders compared to responders. Figure 1 shows DeCyder analysis for B2M and Hp, indicating that these proteins were increased and decreased in abundance levels, respectively, between non-responders and responders to thalidomide-based therapy. Gel images and 3-D protein spot views for Hp and B2M are also displayed, demonstrating a clear difference in the abundance levels (Fig. 1 ).
Protein identification
Subsequently, these proteins of interest were identified by LC-MS/MS using an ion trap LTQ mass spectrometer and searched against the SWISS-PROT database using SEQUEST [20] [21] [22] . The serum Hp fragment, which was the only protein found to have a lower abundance level in nonresponders compared to responders, was identified by LC-MS/MS resulting in nine matched peptides corresponding to a sequence coverage of 11.58% (Table 2) . Proteins found to have higher abundance levels between non-responders and responders to thalidomide-based therapy were ZAG, VDB, SAA and B2M. These proteins were identified by LC-MS/MS resulting in 10, 20, 4, and 3 matched peptides, respectively, corresponding to a 37.63, 53.59, 48.36 and 35.29% sequence coverage, respectively (Table 2) .
DeCyder ratios, ELISA data and ROC curve analysis
In this study, ELISA-based assays were used to measure the levels of the five candidate marker proteins in serum from thalidomide responders and non-responders (Supporting Information Table S1 ). The ELISA-based assays were performed on a larger cohort compared to the 2-D DIGE analysis, consisting of 51 consecutive MM patients (29 responders; 22 non-responders). The five DE protein concentrations were measured in duplicate for each patient.
The box plots show the data for responders and nonresponders (Fig. 2) . The horizontal line within the boxes represents the median. The upper and lower box edges are the 1st and 3rd quartiles. The whiskers reach the nearest value within 1.5 times the inter-quartile range. The points outside the whiskers are considered outliers; however, no outlier value was removed from our analysis. 72  F  II  PD  NR  16  74  M  III  PD  NR  12  71  M  III  PD  NR  19  65  M  II  PD  NR  11  70  M  III  PD  NR  17  63  F  III  PD  NR  14  72  M  III  PD  NR  16  63  M  II  SD  NR  11  78  M  II  PD  NR  10  79  F  II  PD  NR  15  57  F  III  PD  NR  10  77  M  III  PD  NR  12  78  F  II  PD  NR  15  64  F  II  PD  NR  21  65  F  I  SD  NR  20  73  F  III  PD  NR  18  78  M  II  SD  NR  11  61  F  II  SD  NR  12  76  F  III  PD  NR  9  77  M  II  PD  NR  11  62  M  I  PD  NR  8  69  M  II  SD  NR  6 Clinical details include age, sex, ISS (International Staging System), day 100 restaging results based on IMWG uniform response criteria for MM. The last column shows duration of follow-up in months. Abbreviations: CR: complete response; VGPR: very good partial response; SD: stable disease; PD: progressive disease; IMWG: International Myeloma Working Group; R: responders to thalidomide-based therapy; NR: non-responders to thalidomide-based therapy; M: male; F: female.
Non-responders
In clinical practice, it is rare that a chosen cut off point for a single analyte will achieve perfect discrimination between various groups of patients, and one has to select the best compromise between sensitivity and specificity by comparing the diagnostic performance of different tests or diagnostic criteria available. In this study, we assessed the suitability of a panel of proteins for potential clinical application using LR ROC curves and report the AUC of each test. ROC curves allow systematic analysis of the diagnostic performance of a test, a comparison of the performance of different tests, and the AUC provides a summary measure of the utility of the model [23, 24] . In our study, we determined the potential impact of the use of ZAG, SAA, VDB, B2M and Hp as single or combination biomarkers for distinguishing between responders and non-responders to thalidomide-based therapy in MM patients. The ELISA values for each of these five proteins were used to develop multivariate LR models and the subsequent ROC curves generated (Fig. 3) and the AUC determined.
2-D DIGE and ELISA analysis showed that ZAG had a 1.48-(p 5 0.0000022) and a 1.27-fold (p 5 0.00398) increase in abundance levels in non-responders compared to responders, respectively (Table 2) , as determined by univariate analysis. The ROC curve generated from the ELISA data for ZAG yielded an AUC of 0.76 as an individual protein (Fig. 3) . Results for SAA showed a 3.01-fold (p 5 0.006) increase in abundance levels for non-responders compared to responders using 2-D DIGE protein profiling analysis. This result correlated strongly with data from the ELISA analysis, indicating a 3.80-fold (p 5 0.00016) increase in SAA abundance levels in non-responders compared to responders (Table 2) . ROC curves calculated from this ELISA data showed an AUC of 0.82 (Fig. 3) , indicating excellent discriminatory power for this single protein. SAA is a sensitive marker of inflammation [25, 26] . In the 22 non-responder patients studied in this project, none had evidence of infection or fever at the time of sampling; out of 29 responder patients, 1 had an infection resulting in mild fever. Therefore, the SAA elevation in the non-responder patients appeared to be unrelated to infection or inflammation.
Hp is normally removed by the immunodepletion column; however, using 2-D DIGE analysis followed by LC-MS/MS, an $10-kDa Hp fragment was identified [27, 28] . We suggest that this Hp fragment was not removed due to its size and non-interaction with the specific Hp antibody in the affinity column, and hence it was detected in the 2-D DIGE analysis. In the protein profiling analysis, the Hp fragment was found to be 3.01-fold (p 5 0.0015) decreased in serum from non-responders compared to responders. As intact Hp was removed from this analysis because of the immunodepletion column, it was decided to investigate this protein using an ELISA-based assay approach. Data from the ELISA analysis for intact Hp showed a 1.73-fold (p 5 0.03241) decrease in abundance levels in non-responders compared to responder. ROC curves were generated from the ELISA data, which showed an AUC of 0.64 (Fig. 3) . The decrease in abundance of the Hp fragment seen in thalidomide non-responders compared to responders using 2-D DIGE analysis displayed a similar trend to that of the intact Hp detected by ELISA analysis in the unfractionated serum samples (Table 2) .
2-D DIGE data and ELISA results showed a 1.96-(p 5 0.0015) and 2.00-fold (p 5 0.00118) increase, respectively, in the abundance level of B2M from non-responders compared to responders. The ROC curve generated from this data yielded an AUC of 0.87, indicating excellent discriminatory power for this protein (Fig. 3) . The VDB protein level from 2-D DIGE analysis and ELISA data showed a 1.31 (p 5 0.00044) and 1.28 (p 5 0.02045) fold increase in abundance levels, respectively, from nonresponders compared to responders (Table 2) . ROC curves were generated from the ELISA data and showed an AUC of 0.70 (Fig. 3) .
Logistic regression with multiple proteins
Initially, LR was used to develop predictive models for each individual DE protein (Fig. 3) . The best predictive single proteins from the LR model were B2M and SAA, with AUC values of 0.87 and 0.82, respectively. The remaining single protein model had AUC values less than 0.8, indicating poorer predictive ability (Fig. 3) . The predictive capability of models developed based upon combinations of proteins was also assessed. LR models were constructed and ROC analysis carried out on all possible permutations of the DE proteins. The three most successful combinations of biomarkers from this analysis for predicting response to thalidomide-based therapy were found to be Hp, SAA, VDB (Fig. 4) . The sensitivity and specificity of this model was 81.81 and 86.20%, respectively. In this analysis, CRP level at diagnosis was also assessed but did not improve the predictive capability of this model. CRP was found to have a mean of 10.4717.7 mg/mL in responders compared to 12.1723.6 mg/mL in non-responders (p 5 0.770749339). CRP was found to have an AUC of 0.4, indicating no discriminatory power for predicting response to thalidomide-based therapy.
No correlation between clinical parameters such as age and gender and response to thalidomide was found. Also, individual clinical parameters were combined with the model to determine if classification accuracy could be improved. However, no clinical parameter improved classification accuracy for thalidomide response.
Calculation of non-response probability
The equation shown here, allows for the calculation of the probability (p) of a patient being a non-responder based on the serum concentrations of ZAG, Hp and VDB as determined using ELISAs. Each protein concentration in mg/mL is first multiplied by the regression coefficient (derived from the fitted model) as per the equation below. If the resulting value of p is below 0.5, response to thalidomide is predicted and if the value is above 0.5, non-response to thalidomide is predicted. As additional patient data is accumulated from future randomized clinical trials, the Listed are the protein identities obtained by LC-MS/MS analysis, molecular weight (MW), number of matched peptides related to the protein, percentage coverage of the protein sequence identified, XC-Score (Sequest score ), DeCyder ratio with associated p-value (immunodepleted serum) and ELISA ratio (NR/R) with associated p-value (unfractionated serum). The DeCyder ratio for Hp is the $10 kDa fragment identified in the 2-D DIGE analysis while the ELISA ratio is based on the intact form of this protein.
values of the regression coefficients may be altered (Supporting Information Table S2 ).
p ¼ 1 11e ÀððÀ0:001037ÂHpÞ1ð0:017653ÂSAAÞ1ð0:013311ÂVDBÞÀ8:603880Þ
Discussion
Clinical trials of thalidomide have shown variable results [29, 30] . We believe that part of the reason for this is the application of a standardized approach to therapy for a heterogeneous group of patients. There is a significant risk of major acute adverse events (National Cancer Institute Common Toxicity Criteria Grade III-IV) including thrombosis (20%), infection (12%) and irreversible neuropathy (8%) associated with thalidomide-based therapy [31, 32] , which can be both cumulative as well as dose related [33] . Furthermore, the development of severe neuropathy can preclude the future use of other neurotoxic agents including bortezomib. Therefore, it is clearly desirable to develop means to predict responders to thalidomide in order to maximize the benefit to risk ratio in MM patients.
The mechanism of action of thalidomide and its analogues is mediated through modulation of the cells of the microenvironment with anti-inflammatory and immunomodulatory effects [8, 34] . These include downregulation of stromal cell adhesion molecules, inhibition of secretion of angiogenic and survival growth factors, pleiotropic immunomodulatory effects including inhibition of tumor necrosis factor-alpha (TNF-a) secretion, stimulation of IL2 and interferon-gamma (IFNg). Cellular targets include lymphocytes, monocytes and NK cells [35] . In patients with an activated immune system, thalidomide inhibits tumor necrosis factor-a secretion from monocytes [36] and downregulates secretion of stimulatory cytokines including IL1, IL6, IL12 and GMCSF [37] . Conversely, thalidomide has been shown to co-stimulate CD41T cells by CD28 phosphorylation. In vitro, immunomodulatory effects of thali- domide and its analogues therefore vary depending on the level of activation of the patient's immune system. Using 2-D DIGE and MS technologies, we have previously demonstrated novel biomarkers for the early detection of squamous carcinoma of lung [11] and proteins associated with tumor progression in squamous cell carcinoma of the head and neck region [14] . We have adopted a similar scientific approach to the analysis of serum from newly diagnosed MM patients. Interestingly, ZAG, VDB, SAA, B2M and Hp were the five individual proteins with statistically different concentrations between responders and non-responders. A combination of protein biomarkers consisting of serum proteins ZAG, SAA and VDB yielded an AUC of 0.96, indicating an outstanding predictive capability.
B2M is an 11-kD protein associated with the outer membrane of many cells including lymphocytes. It is the small subunit of the MHC class I molecule and is present in small amounts in serum, CSF and urine of normal people. In patients with MM, B2M has been confirmed as a highly significant prognostic factor in combination with albumin as part of the ISS. ZAG is an adipokine with structural organization and folding similar to MHC class I antigen-presenting molecules and therefore may have a role in the immune response [38] . SAA is an apolipoprotein synthesized in response to inflammatory cytokines released by activated monocytes as well as macrophages, and also has a role in fibrosis [39, 40] . Its persistently high concentration is also a prerequisite for the development of AA Amyloidosis [41] . VDB protein is a glycoprotein that functions as the main carrier for vitamin D and its hydroxylated metabolites in the plasma. It is also a precursor for the principal macrophageactivating factor (MAF) [42, 43] . VDB is present on the surface of several cell types including T and B lymphocytes. Hp is a glycoprotein mainly secreted by hepatocytes in response to a variety of stimuli mainly as an acute phase protein and has been shown to have angiogenic effects [44] [45] [46] .
In vitro, it has been shown that thalidomide analogues can have variable effects depending on the immunological status of the patient [35, 47] . Interestingly, four of the five proteins with increased concentration in non-responders to thalidomide are acute phase reactants. However, Hp and CRP, two significant acute phase proteins, were not found to be of higher abundance in the non-responder group so it is unclear if the response is related to acute phase or immune response. Thalidomide has potent anti-angiogenic effects mediated by AKT signaling and secretion of angiogenic cytokines [48] . The observation that Hp, a pro-angiogenic protein, has a higher concentration in responders to thalidomide supports the idea that inhibition of angiogenesis is an important part of disease response to thalidomide.
We considered the possibility that the non-responders were simply patients with disease that would be refractory to all therapies. Of 22 non-responders to thalidomide, 16 successfully achieved CR/VGPR using other therapies including bortezomib and lenalidomide (Supporting Information Table S3 ). This suggests that the biomarker profile is predictive of thalidomide response rather than that the nonresponders were simply patients with MM refractory to all therapies (Supporting Information Table S3 ). Furthermore, these data suggest that, had the non-responsive patients received an alternative to thalidomide as induction therapy, a significant response could have been obtained. The ISS, based on serum B2M and albumin levels, is a predictor of overall survival in MM patients [17, 49] . The endpoint in our study was response to thalidomide in contrast to survival (as applied to the ISS) and we found no correlation between ISS values and response rate to thalidomide. Moreover, incorporation of albumin, B2M and CRP into the Hp/VDB/SAA panel did not improve predictive ability (data not shown).
In conclusion, accurate prediction of sensitivity to thalidomide will help progress toward the goal of personalized medicine in MM patients. We have identified a predictive biomarker panel that has the potential to allow thalidomidebased therapy to be directed to patients with sensitive disease resulting in higher response rates. Avoidance of thalidomide use in patients with unresponsive disease will decrease unnecessary potential side effects including thrombo-embolic disease and irreversible peripheral neuropathy. Better response rates and avoidance of therapy and disease-related complications will increase patient quality of life, reduce cost to health care providers and may impact on survival. However, 2-D DIGE analysis is expensive, labor intensive and requires complex equipment and advanced analytical skills, limiting its applicability to only a minority of clinical centers. ELISA tests are inexpensive, robust, sensitive, specific and widely used in hematopathology laboratories attached to clinical units. For this reason, we validated the results from the 2-D DIGE using commercially available ELISA kits. Validation of this proteomic profile using ELISA in large-scale prospective trials of patients receiving thalidomide in the setting of induction, relapse and post-transplant maintenance is required to further define its clinical utility and to expand this paradigm to other agents.
